| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Xiao Huang | Q92099299 |
| P2093 | author name string | Feng Huang | |
| Aiping Lu | |||
| Hai Lin | |||
| Xiaoyu Chen | |||
| Zhijun Yang | |||
| Yuning Xie | |||
| Ka Hong Wong | |||
| Dongyue Wu | |||
| P2860 | cites work | Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors | Q21245468 |
| Gold nanoparticles as novel agents for cancer therapy | Q27008020 | ||
| Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia | Q27309004 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| CPP-Assisted Intracellular Drug Delivery, What Is Next? | Q28079386 | ||
| The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 | Q28142473 | ||
| The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer | Q28257323 | ||
| A Novel Isoquinoline Derivative Anticancer Agent and Its Targeted Delivery to Tumor Cells Using Transferrin-Conjugated Liposomes | Q28547510 | ||
| Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice | Q33398443 | ||
| Safety of antisense oligonucleotide and siRNA-based therapeutics | Q33438977 | ||
| Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Q33702409 | ||
| Endocytosis of nanomedicines. | Q33987301 | ||
| Metal nanoparticles: a theranostic nanotool against cancer. | Q34477781 | ||
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia | Q34615087 | ||
| Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. | Q34637551 | ||
| Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. | Q34818576 | ||
| MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells | Q35001632 | ||
| First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. | Q35905061 | ||
| Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. | Q35940547 | ||
| A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. | Q35953902 | ||
| Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML | Q36181742 | ||
| Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. | Q36219674 | ||
| Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia | Q36248867 | ||
| Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study | Q58577391 | ||
| The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia | Q60545965 | ||
| Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia | Q60623956 | ||
| Idarubicin-loaded methoxy poly(ethylene glycol)--poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity | Q60911729 | ||
| Repopulation of liver endothelium by bone-marrow-derived cells | Q60998173 | ||
| Quizartinib (AC220): a promising option for acute myeloid leukemia | Q64066440 | ||
| Cytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib | Q64107824 | ||
| Comparative Toxicity Study of Docetaxel and Nanoxel, a Docetaxel-Loaded Micellar Formulation Using Cultured and Blood Cells | Q64115965 | ||
| Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery | Q64239906 | ||
| Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia | Q64245608 | ||
| New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise | Q64253519 | ||
| Nanofiller Reinforced Biodegradable PLA/PHA Composites: Current Status and Future Trends. | Q64899397 | ||
| A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. | Q64911585 | ||
| In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia | Q82594760 | ||
| Biodistribution of 1.4- and 18-nm gold particles in rats | Q82715165 | ||
| FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients | Q83584012 | ||
| Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells | Q84002623 | ||
| Poly (D,L-lactic-co-glycolide) nanoparticles for the improved therapeutic efficacy of all-trans-retinoic acid: a study of acute myeloid leukemia (AML) cell differentiation in vitro | Q84479771 | ||
| Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia | Q84642891 | ||
| Antibody–drug conjugates for cancer: poised to deliver? | Q84974070 | ||
| Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience | Q85053955 | ||
| Drug delivery: Unravelling the stealth effect | Q87294624 | ||
| Advances in treatment formulations for acute myeloid leukemia | Q88996492 | ||
| The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia | Q90260883 | ||
| CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia | Q90340566 | ||
| FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia | Q90433630 | ||
| A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML | Q90473342 | ||
| Acute myeloid leukaemia | Q90760094 | ||
| Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy | Q91525036 | ||
| Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia | Q91545850 | ||
| Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia | Q91557416 | ||
| Current challenges for CAR T-cell therapy of acute myeloid leukemia | Q91575126 | ||
| The future of peptides in cancer treatment | Q92270623 | ||
| Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems | Q92368275 | ||
| Cancer targeting peptides | Q92403765 | ||
| Optimized Synthesis of Biodegradable Elastomer PEGylated Poly(glycerol sebacate) and Their Biomedical Application | Q92519003 | ||
| Systematic review of targeted extracellular vesicles for drug delivery - Considerations on methodological and biological heterogeneity | Q92600046 | ||
| Will CAR T cell therapy have a role in AML? Promises and pitfalls | Q92704253 | ||
| Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3 + 7? | Q92784865 | ||
| Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer | Q92810266 | ||
| Targeting cancer vulnerabilities with high-dose vitamin C | Q92987509 | ||
| A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy | Q93027444 | ||
| Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting | Q93038823 | ||
| Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform | Q36443107 | ||
| Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives | Q36748101 | ||
| Bcl-2-regulated apoptosis: mechanism and therapeutic potential | Q36880621 | ||
| Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development | Q37113900 | ||
| CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia | Q37130525 | ||
| PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model | Q37317709 | ||
| Impact of nanotechnology on drug delivery. | Q37389440 | ||
| Lipid nanocapsules: a new platform for nanomedicine | Q37466945 | ||
| MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells | Q37535249 | ||
| Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance | Q37561973 | ||
| Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia | Q37707099 | ||
| Triazine dendrimers as drug delivery systems: from synthesis to therapy | Q37998820 | ||
| Acute myeloid leukemia in older adults | Q38026008 | ||
| In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? | Q38066847 | ||
| Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers | Q38140496 | ||
| Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. | Q38166533 | ||
| Transferrin receptor-mediated endocytosis: a useful target for cancer therapy | Q38191445 | ||
| Gemtuzumab ozogamicin in acute myeloid leukemia revisited | Q38215269 | ||
| The importance of nanoparticle shape in cancer drug delivery. | Q38241390 | ||
| Nanomedicine based on nucleic acids: pharmacokinetic and pharmacodynamic perspectives | Q38261792 | ||
| Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. | Q38285591 | ||
| Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 | ||
| Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation | Q38724286 | ||
| Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance | Q38738443 | ||
| Paclitaxel: What has been done and the challenges remain ahead | Q38787814 | ||
| New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. | Q38787915 | ||
| The evolving landscape of drug products containing nanomaterials in the United States | Q38823222 | ||
| Delivery of Nanoparticles for Treatment of Brain Tumor. | Q38836752 | ||
| Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date | Q38853466 | ||
| Antibody-targeted nanoparticles for cancer treatment | Q38887307 | ||
| Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles | Q38908299 | ||
| Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells | Q38952704 | ||
| A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia | Q38977151 | ||
| Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia | Q39002734 | ||
| Therapeutic targeting of acute myeloid leukemia stem cells | Q39118867 | ||
| Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. | Q39152702 | ||
| Transferrin-conjugated polymeric nanomedicine to enhance the anticancer efficacy of edelfosine in acute myeloid leukemia | Q39547898 | ||
| pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells | Q39850699 | ||
| In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. | Q39954638 | ||
| Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. | Q41240646 | ||
| A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery | Q41876243 | ||
| Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells | Q42182089 | ||
| Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts | Q43042854 | ||
| Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. | Q43170366 | ||
| Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity | Q43239219 | ||
| Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia | Q43490949 | ||
| T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. | Q44139242 | ||
| Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group | Q46975077 | ||
| Particle size-dependent organ distribution of gold nanoparticles after intravenous administration | Q47249334 | ||
| Advances in targeted therapy for acute myeloid leukaemia. | Q48204144 | ||
| A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells | Q48776292 | ||
| Progress in Nanomedicine: Approved and Investigational Nanodrugs | Q49188363 | ||
| A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia | Q49556327 | ||
| Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles | Q49988714 | ||
| Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia. | Q50606185 | ||
| Improved In Vitro Antileukemic Activity of All-Trans Retinoic Acid Loaded in Cholesteryl Butyrate Solid Lipid Nanoparticles. | Q50782986 | ||
| Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. | Q51738954 | ||
| Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. | Q51778579 | ||
| Gold-cluster degradation by the transition of B-DNA into A-DNA and the formation of nanowires. | Q52013387 | ||
| HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia. | Q52580844 | ||
| FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. | Q52591098 | ||
| Investigational CD33-targeted therapeutics for acute myeloid leukemia. | Q52657685 | ||
| CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. | Q52689076 | ||
| Intracellular fluorescent thermometry and photothermal-triggered drug release developed from gold nanoclusters and doxorubicin dual-loaded liposomes. | Q53645660 | ||
| Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. | Q54160284 | ||
| Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. | Q54341407 | ||
| Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). | Q54964566 | ||
| Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. | Q55456813 | ||
| CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease | Q56901286 | ||
| Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer | Q57106044 | ||
| The Effect of Photothermal Therapy on Osteosarcoma With Polyacrylic Acid-Coated Gold Nanorods | Q57380962 | ||
| Polyethylenimine-based formulations for delivery of oligonucleotides | Q58094490 | ||
| P433 | issue | 4 | |
| P921 | main subject | nanomedicine | Q261659 |
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 1559325819887048 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Dose-Response | Q20181483 |
| P1476 | title | Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia | |
| P478 | volume | 17 |
Search more.